Sample size must be planned carefully to ensure that the research time, patient effort and support costs invested in any clinical trial are not wasted. Item 7 of the CONSORT statement relates to the sample size and stopping rules of studies (see Box 1); it states that the choice of sample size needs to be justified.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Altman DG, Schulz KF, Moher D, et al, for the CONSORT group. The revised CONSORT statement for reporting randomised trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
- 2. Frieman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomised control trial: survey of 71 "negative" trials. N Engl J Med 1978; 299: 690-694.
- 3. Altman DG. Statistics and ethics in medical research: III. How large a sample? BMJ 1980; 281: 1336-1338.
- 4. Gore SM. Assessing clinical trials — trial size. BMJ 1981; 282: 1687-1689.
- 5. Friedman L, Furberg C, DeMets D. Fundamentals of clinical trials. 3rd ed. New York: Springer-Verlag; 1998.
- 6. Gebski V, Marschner I, Keech AC. Specifying objectives and outcomes for clinical trials. Med J Aust 2002; 176: 491-492. <eMJA full text>
Online responses are no longer available. Please refer to our instructions for authors page for more information.
The authors thank Rhana Pike, publications officer, for her assistance in preparing this article.